SequelSEC

MBX Biosciences, Inc. MBX

Pharmaceutical Preparations · CIK 0001776111 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
Unavailable
Fiscal year ended 2025-12-31
Operating income
-$98.06M
Fiscal year ended 2025-12-31
Free cash flow
-$81.88M
Fiscal year ended 2025-12-31

MBX Biosciences, Inc. (MBX) reported net income of -$87.00M for the fiscal year ended 2025-12-31. This page shows 3 annual periods of income statement, balance sheet and cash flow figures normalized from MBX Biosciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

MBX Biosciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
RevenueUnavailableUnavailableUnavailable
Cost of revenueUnavailableUnavailableUnavailable
Gross profitUnavailableUnavailableUnavailable
Operating income-$98.06M-$68.19M-$35.31M
Net income-$87.00M-$61.92M-$32.56M
Research & development$79.16M$57.42M$28.53M
Weighted-average diluted sharesshares 36.51Mshares 10.64Mshares 1.02M
Pretax income-$87.00M-$61.90MUnavailable
Income tax expense$0$0$0
Diluted EPS$-2.38$-5.82$-31.96
Selling, general & administrativeUnavailableUnavailableUnavailable
General & administrative$18.90M$10.78M$6.78M
Selling & marketingUnavailableUnavailableUnavailable

Balance

MBX Biosciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Cash & equivalents$75.29M$49.35M$30.52M
Total assets$385.14M$268.54M$84.18M
Current assets$381.54M$267.29M$83.46M
Total liabilities$15.92M$11.09M$4.29M
Current liabilities$15.50M$11.05M$3.93M
Total equity incl. NCI$369.22M$257.44M-$72.47M
Temporary (mezzanine) equityUnavailable$0$152.36M
InventoryUnavailableUnavailableUnavailable
Accounts receivableUnavailableUnavailableUnavailable
GoodwillUnavailableUnavailableUnavailable
Long-term debtUnavailableUnavailableUnavailable
Accounts payable$2.98M$5.34M$1.39M

Cash flow

MBX Biosciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Operating cash flow-$79.95M-$54.68M-$31.98M
Capital expenditures$1.93M$874.00K$129.00K
Investing cash flow-$83.70M-$160.60M-$30.93M
Financing cash flow$189.59M$234.10M$69.22M
Net change in cash$25.94M$18.83M$6.31M
Stock-based compensation$8.68M$5.22M$2.04M
Common dividends paidUnavailableUnavailableUnavailable
Common share repurchasesUnavailableUnavailableUnavailable
Depreciation & amortizationUnavailableUnavailableUnavailable

Derived

MBX Biosciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2025-12-312024-12-312023-12-31
Free cash flow-$81.88M-$55.56M-$32.11M
Gross marginUnavailableUnavailableUnavailable
Operating marginUnavailableUnavailableUnavailable
FCF marginUnavailableUnavailableUnavailable
SBC / revenueUnavailableUnavailableUnavailable
Current ratio24.62x24.19x21.26x
Revenue YoY growthUnavailableUnavailableUnavailable
Net marginUnavailableUnavailableUnavailable
R&D / revenueUnavailableUnavailableUnavailable
CapEx / revenueUnavailableUnavailableUnavailable
Long-term debt / equityUnavailableUnavailableUnavailable
Effective tax rateUnavailableUnavailableUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open MBX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-07View SEC filing
10-K · Filed 2026-03-12View SEC filing
10-Q · Filed 2025-11-06View SEC filing
10-Q · Filed 2025-08-07View SEC filing
10-Q · Filed 2025-05-12View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.